ESR1 and breast cancer: The study compared BCI and IHC4 for their predictive ability in early and late recurrence in postmenopausal-ER+ patients with node-negative BC who participated in the clinical trial for arimidex, tamoxifen, alone or in combination (Sgroi et al., 2013).